# OnCo record anbl17p1 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/anbl17p1/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "anbl17p1", "NCT03786783" ;
  schema:name "ANBL17P1"@en ;
  schema:alternateName "COG ANBL17P1"@en ;
  schema:description "ANBL17P1 tested whether the antibody dinutuximab, which works against relapsed neuroblastoma, can be given from the very start of treatment alongside induction chemotherapy for newly diagnosed high-risk disease; none of the 42 children had unacceptable toxicity, which opened the way to the randomised trial now under way."@en ;
  schema:url <https://onco.cc/trials/anbl17p1/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03786783>, <https://clinicaltrials.gov/study/NCT03786783?tab=results> ;
  onco:status "positive" ;
  onco:tag "soc-trials" ;
  onco:phase "2" ;
  onco:cancers <https://onco.cc/cancers/neuroblastoma-high-risk/>, <https://onco.cc/cancers/neuroblastoma/>, <https://onco.cc/cancers/childhood-cancers/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/autologous-stem-cell-transplant/> ;
  onco:drugs <https://onco.cc/drugs/dinutuximab/>, <https://onco.cc/drugs/sargramostim/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/topotecan/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/drugs/vincristine/>, <https://onco.cc/drugs/doxorubicin/> ;
  onco:institutions <https://onco.cc/institutions/childrens-oncology-group/> .